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GP. The patients were observed over a period of 12
months. Lung function tests and investigations on the
quality of life were carried out over three visits at inter-
vals of six months (at the beginning, after six months and
after 12 months). The quality of life was measured using
the Quality of Life Asthma (FLA) questionnaires, a vali-
dated disease-specific questionnaire and the EQ-5D (Euro-
Qol). In addition, the treatment costs during the study time
period were documented and evaluated.
RESULTS: During the study, the quality of life of the
control group revealed no changes statistically, while the
patients in the disease management group achieved sig-
nificantly higher values than those at the beginning of the
study. The improvements are related particularly to the
“Physical and Psychic Attributes” of the FLA, although
they can also be seen in the (less sensitive) generic EQ-5D.
Thus, the average EQ-5D value of 62 increased to 72,
while in the control group it dropped from 65 to 60. The
study data additionally shows that considerable savings
are possible with disease management for asthma, espe-
cially concerning hospital services. These savings are
partly counteracted with higher costs in other areas, par-
ticularly medication.
CONCLUSIONS: Disease management for asthma can
lead to an improvement of the patient’s quality of life and
a reduction in treatment costs.
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OBJECTIVE: Good asthma knowledge and compliance
with treatment are critical factors for the success of any
asthma management plan. The purpose of the study was
to examine the QoL with the St. George’s Respiratory
Questionnaire (SGRQ) and a visual analogue scale (VAS).
We developed a short educational program based on the
WHO-EuroPharm Forum Guidelines and assessed its ef-
fectiveness by using a short questionnaire.
METHODS: We selected 32 asthmatics (mean age:
39,75; range: 14,57) with long asthma history. Patients’
QoL was assessed twice, before and three month after an
educational seminar. The results of the two assessments
were analyzed using SPSS statistical software.
RESULTS: On the VAS, in which a score of 100 repre-
sents perfect health, patients’ scores by severity were:
mild—first visit 81.72, second 82.83; moderate—first
visit 69.14, second 69.14. On SGRQ, where high scores
represent worse health status the scores at the first visit
for mild patients were: symptom 150.08; activity 367.47;
impact 399.56; total 917.12. In moderate patients the
scores were: symptom 259.41; activity 501.43; impact
514.37; total 1275.23. At the second visit, scores for mild
patients were: symptom 172.50; activity 339.07; impact
342.20; total 853.78. Moderate patients scored: symp-
tom 282.36; activity 506.28; impact 485.89; total
1274.53. We found 30% improvement in asthma knowl-
edge (p  .01). There were no significant changes in tech-
niques for use of inhalers. The number of patients using a
peak flow meter increased from 15% to 28% and all
were using it correctly and regularly.
CONCLUSIONS: QoL scores did not change substan-
tially, although a slight improvement occurred in the ac-
tivity, impact, and total scores in the mild group. As these
patients were regularly controlled, we expected better
knowledge of general asthma and inhaler use technique.
We can conclude that it is necessary to refresh asthma
knowledge regularly. It is also important to regularly as-
sess patients’ self-management plans by aiming to in-
crease their effectiveness.
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OBJECTIVE: The aim of this study was to define the
main characteristics of patients presenting with an AECB
in general practice.
METHODS: This cross-sectional study was performed
by a representative sample of 120 General Practitioners
(GPs), selected by random pooling from a national data-
base. Each GP was required to recruit prospectively and
consequently a maximum of eight patients aged 35 years
or more with AECB defined by at least one of the Antho-
nisen criteria. Socio-demographics, medical history of
chronic bronchitis and the current episode management
were collected. The Saint-George’s Respiratory Question-
naire (SGRQ) was self-administered by the patients.
RESULTS: One hundred one GPs recruited 417 patients
from November 2000 to April 2001. The patients were
on average 65 years old, with 67% over 60 years.
Twenty nine percent (121) of patients were smokers and
163 (40%) were former smokers. They had been suffer-
ing from chronic bronchitis for an average of 13 years.
During the last 12 months, 351 patients (85%) experi-
enced four or less episodes of AECB (mean  3 episodes),
and 52 patients (12%) were hospitalized due to the dis-
ease. FEV1 was available for 186 patients. The value was
greater than 80% for 14% of the patients, between 35%
and 80% for 76%, and less than 35% for 10%. Most of
the patients were classified as Anthonisen 1 (289 pa-
tients, 69%), and 104 patients (25%) as Anthonisen 2.
The total mean score from the SGRQ was 54 (n  275)
(symptoms 62, activity 63, impact 46) and consistently
increased with age, duration of chronic bronchitis, FEV1,
number of AECB episodes and Anthonisen severity.
CONCLUSION: This observational study confirmed the
importance of risk factors and the severity of AECB in
patients managed by GPs, with significant burden of dis-
ease.
